Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated September 19, 2025, reports a transaction in the company's own shares. The filing details a share repurchase executed on September 18, 2025, through the corporate stockbroker Merrill Lynch International.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding the company's share buyback program. No revenue, profit, cash flow, or debt metrics are disclosed in this specific document.
- Shares Purchased (Sept 18, 2025): 15,858 ordinary shares.
- Price Range: Lowest 1,471.00p; Highest 1,480.00p.
- Volume-Weighted Average Price: 1,476.54p.
- Total Buyback Since June 4, 2025: 29,330,461 ordinary shares.
- Treasury Shares Held: 247,464,844 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,067,938,124 ordinary shares.
- Treasury Voting Rights Percentage: 6.08%.
Material Changes
The filing does not provide comparative financial data against prior periods. The primary change reported is the reduction of shares in issue and the increase in treasury shares resulting from the September 18 transaction, which is part of an ongoing non-discretionary agreement initiated on June 4, 2025.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding future earnings or operational outlook. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties. Investors are directed to the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and the Q2 Results for 2025 for detailed risk disclosures.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback program announced on June 4, 2025.
- Confirm the impact of the 6.08% treasury share holding on earnings per share (EPS) calculations.
- Review the Q2 2025 results and 2024 Form 20-F for comprehensive financial performance and risk factors not included in this transaction report.
- Check if the 15,858 shares purchased on September 18 were the only trades executed that day or if additional trades occurred outside the reported window.